Breast cancer
Conditions
Interventions
Endocrine therapy effective group:None
Endocrine therapy ineffective group:None
Sponsors
Shenzhen Hospital of Southern Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary signing of informed consent form; 2. Age: 18~75, gender: female; 3. Patients with estrogen receptor positive breast cancer (ER+) have been diagnosed according to the Guidelines for Diagnosis and Treatment of breast cancer in China (2022 Edition), the Guidelines for ER and PR Testing of breast cancer in China, the Guidelines for HER2 Testing of breast cancer in China and other guidelines issued by the National Health Commission; 4. Patients who are recommended to use combination therapy of anastrozole and abexili based on the judgment and diagnostic function of the treating physician.
Exclusion criteria
Exclusion criteria: 1. Patients with acute and chronic gastrointestinal diseases; 2. Patients with active pulmonary tuberculosis or other serious infectious diseases, serious heart (cardiac function grade III or IV), lung, liver (chronic hepatitis B or hepatitis C), kidney or other important organ system diseases, and neurological or mental disorders; 3. Multiple sclerosis or other demyelinating diseases; 4. Pregnant women, breastfeeding women, and patients with pregnancy plans; 5. Patients with liver and kidney dysfunction; 6. Individuals with hematological changes (such as leukopenia, thrombocytopenia, or severe anemia); 7. Patients deemed unsuitable by the researchers to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characteristics of intestinal microbiota;Gut microbiota metabolites;Plasma metabolite profile;Plasma proteomic features; | — |
Countries
China
Contacts
Public ContactZhihua Li
Shenzhen Hospital of Southern Medical University
Outcome results
None listed